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ABSTRACT
Objective: To assess the impact on cardiovascular risk
factor management in primary care by the introduction of
chronic kidney disease epidemiological collaboration
(CKD-EPI) for estimated-glomerular filtration rate (eGFR)
reporting.
Design and setting: Cross-sectional study of routine
healthcare provision in 47 primary care practices in The
Netherlands with Modification of Diet and Renal Disease
Study eGFR reporting.
Methods: eGFR values were recalculated using CKD-EPI
in patients with available creatine tests. Patients
reclassified from CKD stage 3a to CKD stage 2 eGFR
range were compared to those who remained in stage 3a
for differences in demographic variables, blood pressure,
comorbidity, medication usage and laboratory results.
Results: Among the 60 673 adult patients (37% of adult
population) with creatine values, applying the CKD-EPI
equation resulted in a 16% net reduction in patients with
CKD stage 3 or worse. Patients reclassified from stage 3a
to 2 had lower systolic blood pressure (139.7 vs
143.3 mm Hg p<0.0001), higher diastolic blood pressure
(81.5 vs 78.4 mm Hg p<0.0001) and higher cholesterol
(5.4 vs 5.1 mmol/L p<0.0001) compared to those who
remained in stage 3a. Of those reclassified out of a CKD
diagnosis 463 (32%) had no comorbidities that would
qualify for annual CVD risk factor assessment and 20
(12% of those with sufficient data) had a EuroSCORE
CVD risk >20% within 10 years.
Conclusions: Use of the CKD-EPI equation will result in
many patients being removed from CKD registers and the
associated follow-up. Current risk factor assessment in
this group may be lacking from routine data and some
patients within this group are at an increased risk for
cardiovascular events.
INTRODUCTION
Chronic kidney disease (CKD) is common and
causes substantial morbidity, mortality and
healthcare expenditure because it is associated
with an increased risk of cardiovascular events
as well as progression to end-stage renal
failure.1–3 Estimated glomerular ﬁltration rate
(eGFRs) are routinely calculated from mea-
sured serum creatine values to assess renal
function.4 The eGFR is central to the classiﬁca-
tion of CKD into different stages and is used
alongside other evidence of kidney disease,
such as structural abnormalities on imaging or
albuminuria. A key consequence of this
staging of CKD is that it is used to guide the
management of cardiovascular risk markers,
the frequency of follow-up and the need for
referral.4 In The Netherlands there is guid-
ance for primary care on how to assess and
manage cardiovascular risk.5
Globally, the standard equation used by
healthcare laboratories to calculate eGFR is the
four variable Modiﬁcation of Diet and Renal
Disease (MDRD) study equation.6 Using pooled
data from diagnostic accuracy studies, a newer
more accurate equation was developed—the
chronic kidney disease epidemiological collab-
oration (CKD-EPI) equation.7–10 Several studies
have shown that use of the CKD-EPI equation
to calculate eGFR leads to a reduction in CKD
diagnoses in younger patients, but an increase
in CKD diagnoses in elderly patients.11 12 Data
from cohort studies and the US health insur-
ance schemes have shown that CKD stage
derived from the CKD-EPI formula better
ARTICLE SUMMARY
Strengths and limitations of this study
▪ A large population-based study using routinely col-
lected healthcare data with generalisable results.
▪ Chronic kidney disease (CKD) categories were
based on one estimated-glomerular filtration rate
measurement.
▪ Not all patients reclassified out of CKD had data
available for cardiovascular risk assessment and
the extent of missed high-risk patients with
CKD-EPI may be underestimated.
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predicts cardiovascular events and cardiovascular risk than
does CKD stage derived from the MDRD equation.13–15
The impact on cardiovascular risk follow-up and man-
agement in primary care arising from the introduction of
the CKD-EPI formula for routine eGFR reporting has not
been assessed. We do know that the CKD-EPI formula will
change the CKD stage of many patients.11 This has import-
ant implications as current guideline-driven care pathways
emphasise different intensities of monitoring and drug
prescribing according to CKD stage. For patients who have
their CKD diagnosis removed entirely (by a shift from an
MDRD-derived eGFR of <60 to a CKD-EPI-derived eGFR
of >60 mL/min/1.73 m2 in the absence of known albu-
minuria or other evidence of kidney disease) this will lead
to a less intensive treatment of cardiovascular risk factors
unless there are comorbid diagnoses such as diabetes mel-
litus that necessitate enrolment in a cardiovascular risk
management programme.
In The Netherlands, all routine chronic disease manage-
ment is undertaken by primary care physicians in
community-based practices, and national guidance on
monitoring is available.4 Reporting of eGFR with serum
creatine in The Netherlands began in 2006 and the
EuroSCORE model for cardiovascular risk assessment is
currently recommended for use in primary care.5 The aim
of the study was to determine the cardiovascular risk
proﬁle of patients who no longer fulﬁlled CKD stage 3 cri-
teria when using the CKD-EPI formula for eGFR reporting.
METHOD
Recruitment of patients
This study used patient data from general practices that par-
ticipated in a cluster randomised controlled trial on the
effect of web-consultation between a general practitioner
(GP) and nephrologist on face-to-face referrals—the
CONTACT study (Consultation of Nephrology by
Telenephrology Allows optimal Chronic kidney disease
Treatment in primary care, Netherlands Trial Registration
code 2368). The CONTACT study recruited practices
during a CKD management course for GPs in the eastern
Netherlands. Forty-seven non-academic general practices
participated and in the current study the latest data were
analysed from their registered populations’ electronic
medical records between 1 January 2008 and 30 June 2011.
Estimation of renal function
eGFRs were calculated for patients aged 18 years or older
using both the MDRD and CKD-EPI equations.6 7 The
most recent serum creatine values were selected and were
either standardised to isotope dilution mass spectrometry
(IDMS) or subject to the appropriate correction factor
for laboratories using the Jaffé technique.16
Patient characteristics
Demographic and clinical data including age, sex, albu-
minuria, comorbidities, medication, blood pressure and
lipid levels were extracted from electronic medical
records (table 3). Albuminuria was divided into microal-
buminuria and macroalbuminuria. Microalbuminuria
was deﬁned as a urinary albumin to creatine ratio (ACR)
of 2.5–25 mg/mmol in men and 3.5–35 mg/mmol in
women. Higher ratios were considered to reﬂect macro-
albuminuria. If the ACR was not available we used a
urine albumin concentration >20–200 mg/L for microal-
buminuria and >200 mg/L for macroalbuminuria.17
Comorbidities were classiﬁed using the International
Classiﬁcation of Primary Care (ICPC) codes as a history
of the following diseases: cardiovascular disease (CVD)
(K74-K77, K89, K90, K92), diabetes mellitus (T90) and
hypertension (K86, K87). Anatomical therapeutic chem-
ical (ATC) codes were used to select prescriptions from
2010, and included ACE inhibitors and angiotensin
receptor blockers (C09), diuretics (C03) and statins
(C10). Blood pressure was reported as the mean of the
two most recent measurements. In order to reduce
potential under ascertainment bias for chronic disease,
if patients were prescribed medications for chronic
disease management without an appropriate code, for
example, antihypertensive medication without hyperten-
sion coded in the medical record, we assumed that the
relevant chronic disease was present, even if not coded.
Analysis
The prevalence of CKD stages derived from the use of the
MDRD and CKD-EPI equations was calculated using the
size of the registered population aged 18 years and over as
the denominator. Demographic and clinical features of
patients reclassiﬁed from CKD stage 3a to stage 2 by using
the CKD-EPI equation were compared with patients who
remained in stage 3a. Next, we speciﬁcally described char-
acteristics and cardiovascular risk proﬁle of patients whose
CKD stage 3a was changed to stage 2 who had no diag-
nosed comorbidity that would otherwise have necessitated
their participation in a cardiovascular risk management
programme. To assess cardiovascular risk proﬁle we
applied the EuroSCORE 10 year risk for CVD.5 To ensure
conservative estimation we assumed negative smoking
status when lacking. Continuous data were compared
using t tests and categorical data were analysed using χ2
tests. Analysis was conducted using SPSS V.20.0 (IBM
PASW statistics 20).
RESULTS
Practice population
The 47 study practices serve a population of 207 469
people of whom 162 562 were over 18 years of age.
Between 2008 and 2011, 37% of all adults registered
with these practices (n=60 673) had their serum creatine
measured. In the over 65 age group this ﬁgure rose to
71% (20 959 out of 29 591).
Study population
The use of the CKD-EPI equation changed the CKD
stage for 20% of patients (n=12 278) with a measured
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serum creatine value. This reclassiﬁcation resulted in a
16% net reduction in the total number of individuals
with CKD stage 3 or worse: 1428 patients were reclassi-
ﬁed from stage 3a to stage 2, whereas 195 patients were
reclassiﬁed from stage 2 to stage 3a (table 1). As a conse-
quence the prevalence of detected CKD stages 3–5
declined from 4.8% to 4.0% in the total adult
population.
Thirty-two per cent (n=19 235) of those who had a
serum creatine measurement also had a urine assess-
ment to evaluate albuminuria, and the numbers of
patients with different levels of albuminuria are shown
in table 2, stratiﬁed by eGFR category using both MDRD
and CKD-EPI eGFRs. Overall in those tested, the preva-
lence of microalbuminuria was 12.1% (n=2322) and of
macroalbuminuria was 1% (n=284). Of the patients
reclassiﬁed from CKD stage 3a to stage 2 eGFR range,
albuminuria was tested for in 43% (n=617) and the
prevalence of microalbuminuria was 8.6% (n=53) and of
macroalbuminuria was 1.5% (n=9).
Patients reclassified out of CKD compared to patients
remaining in stage 3a
Compared to patients whose CKD stage remained 3a,
those who were reclassiﬁed to stage 2 range eGFR using
the CKD-EPI equation were younger, more were female,
with less microalbuminuria, a comparable prevalence of
macroalbuminuria, fewer comorbidities and were
prescribed fewer antihypertensive and lipid-lowering
drugs (table 3). Systolic blood pressure was signiﬁcantly
lower and diastolic blood pressure signiﬁcantly higher in
patients reclassiﬁed out of CKD. Total cholesterol and
low-density lipoprotein (LDL)-cholesterol were signiﬁ-
cantly higher in this group.
Patients reclassified out of CKD without other diagnosed
comorbidities
A total of 463 patients (32% of those reclassiﬁed out of
CKD) would be removed from a cardiovascular risk man-
agement programme as they were not diagnosed with
other comorbidities (table 4). Cholesterol measurement
was performed in 64% of patients. The majority of
patients had not had an albuminuria assessment. Blood
pressure was measured in 218 patients and 111 (51%) of
them had elevated values ≥140/90 mmHg requiring
further monitoring. Similarly, 20 of 172 patients (12%)
with sufﬁcient data to complete cardiovascular risk assess-
ment had a EuroSCORE 10 year CVD risk of >20%.
Patients reclassified into a CKD diagnosis
A total of 195 patients were reclassiﬁed from stage 2 to
stage 3a CKD, and of these, 166 (85%) had existing
comorbidities that would already have identiﬁed them
for cardiovascular risk assessment. Among the 29
patients who had no identiﬁable comorbidity, their
mean age was 85.4 years (SD 5.1, youngest 76 years) and
Table 1 Reclassification of primary care patients when using CKD-EPI instead of MDRD
eGFR categories with MDRD (mL/min/1.73 m2)
eGFR categories with CKD-EPI (mL/min/1.73m2)
Total>90 60–89 45–59 30–44 15–29 <15
>90 15 195 741 0 0 0 0 15 936
60–89 9580 27 184 195 0 0 0 36 959
45–59 0 1428 4338 146 0 0 5912
30–44 0 0 106 1345 63 0 1514
15–29 0 0 0 9 290 7 306
<15 0 0 0 0 3 43 46
Total 24 775 29 353 4639 1500 356 50 60 673
CKD-EPI, chronic kidney disease epidemiological collaboration; eGFR, estimated-glomerular filtration rate; MDRD, Modification of Diet and
Renal Disease Study.
Table 2 Numbers of patients with proteinuria according to estimated eGFR category with either MDRD or CKD-EPI in 19235
primary care patients with available results of urine analysis
eGFR categories (mL/min/1.73 m2
>90 60–89 45–59 30–44 15–29 <15
MDRD eGFR
Macroalbuminuria 37 97 67 55 21 7
Microalbuminuria 437 1140 489 219 35 2
No albuminuria 3016 10768 2297 496 51 1
CKD-EPI eGFR
Macroalbuminuria 43 98 61 53 21 8
Microalbuminuria 516 1089 442 226 47 2
No albuminuria 4678 9617 1783 490 58 3
CKD-EPI, chronic kidney disease epidemiological collaboration; eGFR, estimated-glomerular filtration rate; MDRD, Modification of Diet and
Renal Disease Study.
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in the 11 patients with recorded BP, mean values were
137.5 mm Hg (SD 13.7)/71.4 mm Hg (5.4). Of the eight
patients with sufﬁcient data for CVD risk scoring, six
patients were >20%, although all were outside the age
range for accurate scoring and may qualify for high-risk
status on age alone.
DISCUSSION
Principal findings
Application of the CKD-EPI equation to our study popu-
lation resulted in a net 16% decrease (prevalence from
4.8% to 4.0%) in the total number of individuals with
CKD stage 3 or worse based on eGFR criteria. Patients
reclassiﬁed from stage 3a to stage 2 were younger, more
were female with lower prevalence of comorbidities and
a differential effect was seen on blood pressure with
lower systolic but higher diastolic mean values. Although
32% of patients reclassiﬁed out of stage 3a had no docu-
mented comorbidity that would entail annual CVD risk
factor assessment as part of a chronic disease manage-
ment programme, an estimated 12% of these patients
did indeed have elevated CVD risk. Not all reclassiﬁed
patients had an adequate CVD risk factor assessment so
Table 3 Characteristics of patients reclassified out of CKD compared to those who remained in stage 3a
Variable
Remained in
stage 3a (N=4338)
No of
available data
Reclassified out
of CKD (N=1428)
No of
available data
P for
comparison
Age 74.0 (9.5) 4338 60.3 (9.5) 1428 <0.0001
Female 61% N=2654 4338 76% N=1087 1428 <0.0001
Cardiovascular disease 36% N=1566 4338 18% N=250 1428 <0.0001
Hypertension 57% N=2463 4338 47% N=666 1428 <0.0001
Diabetes 26% N=1134 4338 17% N=243 1428 <0.0001
None (also excluding albuminuria) 21% N=924 4338 39% N=557 1428 <0.0001
Statins 46% N=2000 4338 33% N=475 1428 <0.0001
ACE inhibitors and/or Angiotensin II
receptor antagonists
54% N=2349 4338 37% N=533 1428 <0.0001
Diuretics 43% N=1862 4338 26% N=367 1428 <0.0001
Creatine in µmol/L 102 (14.3) 4338 93 (11.4) 1428 <0.0001
Cholesterol/HDL ratio 4.2 (1.4) 3338 4.3 (1.6) 1118 0.020
Total cholesterol in mmol/L 5.1 (1.2) 3498 5.4 (1.1) 1157 <0.0001
HDL in mmol/L 1.31 (0.40) 3454 1.36 (0.41) 1150 <0.0001
LDL in mmol/L 3.05 (1.02) 3451 3.31 (1.01) 1150 <0.0001
Triglycerides in mmol/L 1.65 (0.83) 3458 1.64 (1.05) 1156 0.616
Albumin/creatine ratio* 1.0 (0.9–2.5) 2092 0.9 (0.7–1.2) 583 <0.0001
Albumin urine in mg/L* 6.0 (2.9–17.0) 1174 3.0 (2.0–8.0) 348 <0.0001
Microalbuminuria 410 2161 53 617 <0.0001
Macroalbuminuria 55 2161 6 617 0.113
Diastolic blood pressure in mm Hg 78.4 (9.4) 3540 81.5 (9.0) 1043 <0.0001
Systolic blood pressure in mm Hg 143.3 (17.5) 3540 139.7 (15.8) 1042 <0.0001
*Values are mean (SD) or median (first, third quartile). Percentages of prevalence are calculated with the denominator of available data.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 4 Characteristics of patients reclassified out of CKD without diagnosed comorbidity
Mean (SD)
No of patients with
available data
Age 56.6 (10.0) 463
Female 79% 463
Creatine in µmol/L 97 (11.9) 463
Chol/HDL ratio 4.4 (1.6) 285
Total cholesterol in mmol/L 5.8 (1.0) 295
HDL in mmol/L 1.44 (0.43) 290
LDL in mmol/L 3.78 (0.89) 289
Triglycerides in mmol/L 1.42 (0.76) 289
Albumin/creatine ratio 0.9 (0.5–0.9) 65
Albumin urine in mg/L 2.9 (2.0–5.25) 38
Diastolic blood pressure in mm Hg 81.8 (9.1) 218
Systolic blood pressure in mm Hg 138.0 (16.7) 218
Either systolic or diastolic blood pressure ≥140/90 mm Hg 111 218
EuroSCORE 10 year cardiovascular disease risk ≥20% 20 172
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our results may underestimate the scale of this problem,
although it is still likely that CKD-EPI reclassiﬁcation has
reduced the number of low-risk patients in stage 3.
Differences in prevalence of prescribed lipid lowering
therapy may explain why higher total cholesterol and
LDL levels were seen in patients who were reclassiﬁed to
a higher eGFR value, above the 60 mL/min/1.73 m2
cut-off. Higher prevalence of comorbidities, in patients
in CKD stage 3 using CKD-EPI estimation, are indica-
tions for improved risk factor control for primary and
secondary prevention are likely to explain the greater
statin prescribing and lower lipid levels in patients
retaining a stage 3 CKD diagnosis. However, the differ-
ences in blood pressure are not explained by differences
in antihypertensive prescribing, due to the differential
effect on systolic and diastolic blood pressure.
Strengths and limitations of this study
One of the strengths of our study is the use of routine
general practice data from a large population which
enhances the generalisability of our results. In the absence
of a screening programme, existing CKD diagnoses are
made from clinician-directed testing and so cannot
provide true population prevalence. However, we were
able to include a large proportion of the (potential) CKD
population as creatine results were known in 71% of
patients over 65 years of age. A strength of the analysis of
patients reclassiﬁed from stage 3 CKD to stage 2 eGFR
range is that we made the conservative assumption that
patients prescribed medication used to treat comorbidities
did indeed have that comorbidity, even if it was not coded
in the medical record. This will have the effect of reducing
the number of patients in the subgroup without comorbid-
ity reclassiﬁed out of a CKD diagnosis, and the impact that
we did ﬁnd is likely to underestimate the effect of reclassiﬁ-
cation. Furthermore, our study accurately reﬂects the
changes in CKD stage and status that will arise from use of
the CKP-EPI formula in current clinical practice with
clinician-directed testing.
A limitation of this study is that our classiﬁcation of
patients was based on a single creatine result, whereas
guidelines recommend two measurements ≥3 months
apart before making a diagnosis. However, this is
unlikely to affect the proportional changes seen to a
great extent given the size of our dataset and is in line
with the approach used in most CKD studies.11 12 18–20
Albuminuria and cardiovascular risk factor assessment
were incomplete and this highlight an area for quality
improvement in general practice. However, despite the
low usage of albuminuria assessment, our estimates of
the gains and losses in CKD diagnoses are likely to be
reliable. We did not have ethnicity data and assumed
our population to be Caucasian. This assumption was
based on ethnicity data from the Statistics Netherlands
that shows 92% of the population is Caucasian in the
eastern Netherlands.21 Both MDRD and CKD-EPI equa-
tions estimate true GFR and are therefore prone to
some degree of error.
Comparison with existing literature
In other studies, a similar decrease in CKD prevalence
was found: from 4.2% to 3.9% and 4.9% to 4.4% in two
large adult UK population-based studies,18 and from
5.41% to 4.80% in the Quality Improvement in CKD
trial.22 Also, CKD stage alteration in one-ﬁfth of all
patients with a creatine measurement by use of the
CKD-EPI equation is a ﬁgure consistent with previous
estimates.11
Cohort studies stratifying patients at baseline with reclas-
siﬁed CKD stages using CKD-EPI eGFRs report lower car-
diovascular events in these patient groups during
follow-up,13–15 suggesting that overall, risk prediction is
improved. Two studies that analysed the characteristics of
patients reclassiﬁed out of a CKD diagnosis using CKD EPI
are in agreement with our results, ﬁnding that these
patients were predominantly women, of younger age and
with less diabetes compared to those whose CKD stage
remained unchanged.19 23 White et al19 did not report dia-
stolic blood pressure or LDL-cholesterol levels, but found
that those reclassiﬁed out of CKD had lower systolic blood
pressure, similar total cholesterol levels and lower triglycer-
ides levels and a lower 10-year CVD risk. Although we also
found lower systolic blood pressure levels, we found higher
total (and LDL) cholesterol and no reduction in triglycer-
ide levels. The differential effect on systolic and diastolic
blood pressure may be explained by the fact that the
reclassiﬁed patients in our study had a younger mean age.
Diastolic blood pressure has been shown to be high in
early middle age and then fall in older age as systolic
blood pressure increases.24 Patients with a CKD-EPI eGFR
sufﬁciently higher than their MDRD eGFR to lose their
CKD diagnosis are young enough to exhibit this effect.
Korhonen et al20 found no signiﬁcant differences in
cardiovascular risk factors between those reclassiﬁed and
those remaining in the same CKD stage when the
CKD-EPI formula was used, but the study size (n=1747)
was probably too small to detect the differences we iden-
tiﬁed. No previous study has examined medication use.
Meaning of the study
Introduction of CKD-EPI to calculate eGFR can be
expected to lower primary care workload and reduce
treatment and costs in patients who overall have low car-
diovascular risk. While the CKD-EPI equation shows
greater calibration than the MDRD equation in that it
more accurately stratiﬁes patients in terms of their car-
diovascular risk, we have found that by using routinely
collected data in primary care, patients reclassiﬁed out
of CKD had a more favourable cardiovascular proﬁle in
terms of age and comorbidity compared to patients who
remained in stage 3a. However, there is a small group of
patients with elevated cardiovascular risk who will no
longer be detected and managed.
Unanswered questions and future research
Uncertainty remains about the impact on patient cardio-
vascular follow-up in those who lose their CKD diagnosis
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with use of the CKD-EPI formula. Although fewer car-
diovascular events are seen in patients reclassiﬁed from
retrospective observational data,13–15 their care would
have been guided by MDRD staging rather than the less
severe CKD stage seen with CKD-EPI. Prospective
follow-up studies are therefore required to appropriately
determine the impact of CKD-EPI GFR estimation on
cardiovascular events.
Current guidelines apply a ﬁxed eGFR threshold to
deﬁne CKD with the result that some patients will not be
diagnosed with CKD in the presence of reduced renal
function for their age group. This effect may be particu-
larly relevant in younger patients, who may for example,
have a ‘normal’ eGFR of 80 mL/min/1.73 m2 which is
‘normal’ according to Dutch guidelines4 yet it is signiﬁ-
cantly lower than the average GFR in people of a similar
age.25 It may be more appropriate to report the statistical
deviation of eGFR values from age-matched population
mean and to highlight those that lie below a given percent-
ile for further assessment and cardiovascular risk assess-
ment. The CKD-EPI equation would make such an
approach more feasible since it can be used to accurately
report on eGFR >60 mL/min/1.73 m2.8 Further research
is therefore needed to determine the feasibility of age-
matched eGFR reporting to guide patient management.
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